Inclusion Criteria:

- IIIA NSCLC patients according to TMN-staging of Lung Staging Standard version 7 2009,
confirmed by histopathology or cytology after radical operation, and having EGFR exon
19 deletion mutation or exon 21 L858R single base substitution;

- Accept study adjuvant therapy within 4 weeks post radical operation;

- ECOP PS 0-1; Life expectancy ≥12 weeks;

- Hematology: absolute neutrophil count (ANC) ≥1.5×10^9/L; platelet count ≥100×10^9/L;
hemoglobin concentration ≥ 9.0 g/dL (permit to maintain hematologic criteria by blood
transfusion);

- Liver Function: TBil ≤1.5xULN; ALT and AST ≤2.5xULN;

- Renal Function: Cr ≤1.25xULN, and Ccr ≥60ml/min;

- Female patients of childbearing potential must have a negative serum or urine
pregnancy test within 7 days before study treatment;

- Signed inform consent form by patient or his/her legal representative;

- Comply with study protocol and procedure, and be able to take oral medication; Aged
≥18 years and ≦75 years;

- Eligible patients of reproductive potential (both sexes) must agree to use a reliable
method of birth control before enrollment, during the study period and for at least
30 days after their last dose of study therapy;

Exclusion Criteria:

- Having treated by Her-Target therapy, i.e. erlotinib, gefitinib, cetuximab,
trastuzumab;

- Having treated by any systemic anti-tumor therapy of NSCLC, including cytotoxic
therapy, target medication treatment (i.e. monoclonal antibody), investigational
therapy;

- Having local radiotherapy of NSCLC; Upper gastrointestinal physiological disorders,
or malabsorption syndrome, or intolerance of oral medication, or active peptic ulcer;

- The findings in radical operation are lymph nodes with extracapsular invasion, or
fusion, or all of dissection lymph nodes positive by pathology;

- Diagnosed other malignant tumor besides NSCLC within 5 years prior the study
treatment (except having simple surgical resection with 5-year disease free
survival,cured in situ of cervical carcinoma, cured basal cell carcinoma and bladder
epithelial tumor);

- Confirmed recurrent cancer by Clinical objective evidence (pathology or radiography
images) before the study adjuvant therapy;

- Known hypersensitivity to platinum, Vinorelbine, EGFR-TKI agents or relevant
components in the formulation;

- Uncontrolled eye inflammation or infection, or any potential circumstances lead to
eye inflammation or infection;

- Active interstitial lung disease (ILD) by any clinical evidence; patients with any
co-morbidities, or motalic disorders, or any abnormal findings in physical
examination or laboratory tests are suspected to have contraindication of study
therapy or high risk of study treatment complications;

- Any unstable systemic disease, including active infection, uncontrolled hypertension,
unstable angina, angina starting in latest 3 months, Congestive heart failure (NYHA ≥
II), myocardial infarction within 6 months prior enrollment, under medication
treatment of severe arrhythmia, liver, renal or metabolic disease;

- know HIV infection Pregnant or breastfeeding women;

- ECOG PS ≥2;

- Mixed with small cell lung cancer;

- Other conditions investigators evaluate that patient is not eligible to this study.